![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, August 15, 2016 12:14:56 PM
and does end up with product, how much of a "cut" do Jay Sharma and Celprogen get?
Technically MNZO is the assigned patent holder of a worthless patent. No details were ever given per the patent assignment. All that is known is Kenny got some MNZO stock for having arranged it.
In the real world, if there was any possibility of marketing such a product, Kenny&Sharma would've tried for private equity funding, with the patent assigned to Celpro. Ran Phase 1-2 trials, assuming the FDA would even approve such trials. Then put up the For Sale sign soliciting a big Pharma buyer for Celpro. And/or an IPO on the big board soliciting a Pharma partner.
Instead in the fantasy Microcrap world, Kenny&Sharma play games with MDIN, and footsie with the likes of Barton in MNZO. Objective: To fleece retail so called "investors", with imaginary products, and P&Ds. Now that's on hold with the SEC after Kenny.
The Jewel of the Mind is Colored with the Hue of what it Imagines
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM